Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy

NCT00955929 | Terminated Results DMC

• 1 other identifier: 09-005
• Study Type: interventional
• Target: 76
• Locations: 1 country
• Sites: 1

Brief Summary

When a bilateral nerve-sparing radical prostatectomy (RP) is performed, recovery of erectile function (rigid erections) is reported for up to 80% of patients, who are less than 60 years old. Erectile function recovery is also impacted by patient age, erectile function before surgery, and the length of time after surgery. Current evidence from studies suggests that developing erections is important, however, these studies have been small, and the evidence is not definite. Animal studies suggest that erection medication (Viagra, Levitra, Cialis) may protect erection tissue, even in the absence of erections. However, the correct treatment plan is unknown. For example, how often does a man need to take sildenafil (Viagra®) to protect his erectile function or to maximize his erectile function recovery? Is only using erection medication enough for erectile function recovery? Would penile injections, which almost ensure production of an erection, be better than using sildenafil (Viagra®), or might a combination be even better at helping recovery of erections? These are types of questions this study might answer.

Conditions

Penile Cancer; Erectile Dysfunction; Radical Prostatectomy

Keywords

Penis; PLACEBO; SILDENAFIL CITRATE; TRIMIX; Bimix; Viagra; 09-005; Erectile Dysfunction following Bilateral Nerve-Sparing

Outcome Measures

Primary Outcomes (1)

• Difference in the Erectile Function (EF) Domain Score of the International Index of Erectile Function (IIEF) Between the 3 Groups at 24 Months.

  2 years

Secondary Outcomes (3)

• The Time to Return of Spontaneous Functional Erections.

  2 years

• The Time for Patients to Respond to Oral Erectogenic Therapy.

  2 years

• The Proportion of Patients Who Have Normalization of Their Erectile Function (Normalization of the EF Domain of the IIEF).

  2 years

Study Arms (3)

PRN Sildenafil

EXPERIMENTAL

Placebo QHS (blinded) and sildenafil 100mgs (open-label) as required for sexual relations. The placebo will be omitted on nights that 100mgs is used. Placebo will start within 24-48 hours post-surgery.

Drug: Placebo QHS and sildenafil and questionnaires

Nightly Sildenafil Arm

EXPERIMENTAL

Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery.

Drug: Sildenafil and questionnaire

Combination Therapy Arm

EXPERIMENTAL

Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL), at initial dose of 5 units (0.05ml) will be given; the first 2 injections will be done in the MSKCC urology outpatient clinic (if needed, the investigator can determine appropriate amount of injections for patient training).

Drug: Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires

Interventions

Placebo QHS and sildenafil and questionnaires DRUG

Pts will be offered sildenafil 100 mg to be used before intercourse on an as-required basis. They will be given six 100 mg doses, per month, for a 12-month duration. Each patient in this group will use a placebo pill (blinded) each night, except on a nights that 100mg is taken for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.

PRN Sildenafil

Sildenafil and questionnaire DRUG

Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window

Nightly Sildenafil Arm

Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires DRUG

Intracavernous injections of a trimix combination (Papaverine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL) will be injected three times a week, and sildenafil 50mg taken on the other four (non-injection) nights. Injection therapy can be used for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.

Combination Therapy Arm

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male, must be ≥ 18 years of age, with histologically confirmed prostate adenocarcinoma, that is clinically localized to the prostate gland
• Stable sexual relationship for ≥ 6 months
• Open or laparoscopic bilateral nerve-sparing radical prostatectomy
• Baseline score of ≥ 22 on the International Index of Erectile Function Domain (Appendix A)
• Able to speak, read and write in the English language
• Calculated creatinine clearance using the 4 variable MDRD equation based on serum creatinine, age, race, and gender of \> 60 cc/min
• Patient is able to walk up two flights of stairs briskly without chest pain
• Patient needs to have their baseline sitting AND standing blood pressure and pulse done at the time of consent

You may not qualify if:

• Preoperative or planned postoperative pelvic radiation therapy
• Preoperative or planned postoperative androgen deprivation
• Presence of Peyronie's disease at baseline
• Presence of a penile prosthesis at baseline
• Resection of one or both nerve bundles at surgery
• Any contraindications to sildenafil:
• Patient is currently using nitrates;
• Presence of retinitis pigmentosa;
• Presence macular degeneration;
• MI or CVA within 3 months;
• Patient is currently using MAOI medications
• Patient is currently using penile self injection medication (Trimix, Bimix, or PGE-1)
• Patient requiring sildenafil for penetration
• Use of sildenafil within 30 days of consent

Sponsors & Collaborators

• Memorial Sloan Kettering Cancer Center: lead
• Pfizer: collaborator

Study Sites (1)

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

Location

Related Links

• Memorial Sloan Kettering Cancer Center

MeSH Terms

Conditions

Penile Neoplasms; Erectile Dysfunction

Interventions

Sildenafil Citrate; Surveys and Questionnaires; Alprostadil

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Penile Diseases; Male Urogenital Diseases; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological; Mental Disorders

Intervention Hierarchy (Ancestors)

Sulfonamides; Amides; Organic Chemicals; Sulfones; Sulfur Compounds; Piperazines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health; Prostaglandins E; Prostaglandins; Eicosanoids; Fatty Acids, Unsaturated; Fatty Acids; Lipids; Fatty Acids, Monounsaturated; Autacoids; Inflammation Mediators; Biological Factors

Results Point of Contact

• Title: John Mulhall, MD
• Organization: Memorial Sloan Kettering Cancer Center

mulhalj1@mskcc.org

646-888-6024

Study Officials

• John Mulhall, MD

  Memorial Sloan Kettering Cancer Center

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 7, 2009
• First Posted: August 10, 2009
• Study Start: August 6, 2009
• Primary Completion: December 9, 2020
• Study Completion: December 9, 2020
• Last Updated: November 10, 2021
• Results First Posted: November 8, 2021

Record last verified: 2021-11

Locations

US (1)